Eli Lilly and Company (LLY)

$1,136.37 -8.31 (-0.73%)
Market Cap 1,082.20B
Revenue (ttm) 65.18B
Net Income (ttm) 20.64B
EPS (ttm) N/A
PE Ratio 38.46
Forward PE 31.60
Profit Margin 31.67%
Debt to Equity Ratio 1.26
Volume 2,690,976
Avg Vol 3,286,170
Day's Range N/A - N/A
Shares Out 941.74M
Stochastic %K 71%
Beta 0.53
Analysts Strong Sell
Price Target $1,246.46

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
MF__DOOM
MF__DOOM Jun. 10 at 9:59 PM
$NVO $LLY careful in both
0 · Reply
ripster47
ripster47 Jun. 10 at 8:09 PM
$LLY Bullish Trade on Morgan Stanley’s Overweight Rating & $LULU Earnings Curl Long Setup! Watch the video to learn how to trade this repeatable pattern 🎯 https://x.com/TENETTRADEGROUP/status/2064801272528814173?s=20
0 · Reply
FibonacciTrader_
FibonacciTrader_ Jun. 10 at 7:32 PM
FiercePharma just dropped an update on the weekly charts for $NVO’s Oral Wegovy and $LLY’s Foundayo. Quick note: the latest week only includes 4 business days because of Memorial Day, so interpret the volume/units data with that in mind. Even with the shortened week, these names are showing strong traction in the obesity treatment space, worth tracking for trends and potential upside in pharma plays.
0 · Reply
SecEdgarWhisperer
SecEdgarWhisperer Jun. 10 at 7:19 PM
$LLY As stated before.. ripe for shorting.. I am waiting for the trend reversal confirmation but this could be the begining of market coming to senses and start the distribution..
0 · Reply
janthony23
janthony23 Jun. 10 at 5:33 PM
$LLY - Adding to already large position https://finviz.com/news/360902/zepbound-tirzepatide-and-shaquille-oneal-launch-national-campaign-after-nba-legend-learns-the-obstructive-sleep-apnea-he-has-lived-with-for-years-is-treatable
0 · Reply
janthony23
janthony23 Jun. 10 at 5:06 PM
$LLY + $NVDA https://247wallst.com/investing/2026/06/10/i-would-rebuild-my-portfolio-with-just-these-3-stocks-if-i-lost-everything-tomorrow/
0 · Reply
Pennysluts
Pennysluts Jun. 10 at 4:25 PM
$LLY
0 · Reply
Nosecandy_Bear
Nosecandy_Bear Jun. 10 at 4:07 PM
$LLY $NVO it’s simple! Buy Lilly and hold forever.
0 · Reply
freedomtrader6
freedomtrader6 Jun. 10 at 3:40 PM
$NVO $LLY $HIMS This GLP-1 demand story is getting crazier by the week 🚨 Wegovy pill already has 10,000+ people on a UK waiting list… and it’s not even approved yet. What stood out to me most: 75% of people waiting have NEVER used a GLP-1 before Approval could happen within weeks according to Chemist4U CEO That tells me this isn’t just existing users switching formats… This market is EXPANDING fast Feels like we’re still early in the obesity drug adoption curve, honestly.
2 · Reply
SwingTraderPro1
SwingTraderPro1 Jun. 10 at 3:16 PM
Almost done with my Eli Lilly deep dive Been a long ride holding $NVO - one of the toughest positions in my portfolio. Thesis still intact, but wanted to stress-test it fully. How? By studying the competitor: $LLY. Spent 2 months digging into their business, pipeline, and strategy. Came out understanding $NVO, $LLY, and the GLP-1 space on a whole new level. This deep dive will be a must-read for $NVO or $LLY holders- and anyone looking to navigate the GLP-1 boom. Dropping later this week. Stay tuned.
0 · Reply
Latest News on LLY
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Jun 10, 2026, 6:02 AM EDT - 12 hours ago

Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Eli Lilly: FDA approves Ebglyss for one maintenance dose every eight weeks

2026-06-09T22:25:12.000Z - 23 hours ago

Eli Lilly: FDA approves Ebglyss for one maintenance dose every eight weeks

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

Jun 9, 2026, 6:18 PM EDT - 23 hours ago

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

Jun 9, 2026, 6:06 PM EDT - 1 day ago

As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

HUM MDT UNH

Eli Lilly and Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 3:20 PM EDT - 1 day ago

Eli Lilly and Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Is It Too Late To Buy The Rally In Eli Lilly Stock?

Jun 9, 2026, 2:03 PM EDT - 1 day ago

Is It Too Late To Buy The Rally In Eli Lilly Stock?

Eli Lilly price target raised to $1,350 from $1,330 at Jefferies

2026-06-09T15:57:22.000Z - 1 day ago

Eli Lilly price target raised to $1,350 from $1,330 at Jefferies

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 1 day ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ MRK NVO PFE

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

Jun 9, 2026, 4:00 AM EDT - 1 day ago

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 1 day ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY MRK PFE RDW UTHR XBI

Use of GLP-1 drugs early in pregnancy should not cause alarm

Jun 8, 2026, 5:05 PM EDT - 2 days ago

Use of GLP-1 drugs early in pregnancy should not cause alarm

NVO

Eli Lilly reports detailed results from three Phase 3 trials in ACHIEVE program

2026-06-08T18:35:36.000Z - 2 days ago

Eli Lilly reports detailed results from three Phase 3 trials in ACHIEVE program

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Jun 8, 2026, 2:30 PM EDT - 2 days ago

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead

Jun 8, 2026, 1:50 PM EDT - 2 days ago

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead

Eli Lilly Stock (LLY) Jumps 4%. The Outlook for Its Weight-Loss Drugs Just Keeps Getting Better

2026-06-08T14:30:45.000Z - 2 days ago

Eli Lilly Stock (LLY) Jumps 4%. The Outlook for Its Weight-Loss Drugs Just Keeps Getting Better

NVO

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Jun 8, 2026, 10:30 AM EDT - 2 days ago

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

NVO

Monday's Morning Movers: MU & SNDK PT Hikes, LLY Foundayo Delivers

Jun 8, 2026, 10:30 AM EDT - 2 days ago

Monday's Morning Movers: MU & SNDK PT Hikes, LLY Foundayo Delivers

SNDK MU

‘This Is Compelling’: Citi Pounds the Table on Eli Lilly (LLY) Stock

2026-06-08T13:55:35.000Z - 2 days ago

‘This Is Compelling’: Citi Pounds the Table on Eli Lilly (LLY) Stock

Lilly shares jump as analysts see retatrutide data extending obesity market edge

Jun 8, 2026, 7:06 AM EDT - 2 days ago

Lilly shares jump as analysts see retatrutide data extending obesity market edge

Novo Nordisk Stock (NVO) Drops despite Obesity Updates as Eli Lilly Takes All the Shine

2026-06-08T10:21:55.000Z - 2 days ago

Novo Nordisk Stock (NVO) Drops despite Obesity Updates as Eli Lilly Takes All the Shine

NVO

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Jun 8, 2026, 6:16 AM EDT - 2 days ago

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Jun 8, 2026, 5:44 AM EDT - 2 days ago

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

Jun 8, 2026, 5:35 AM EDT - 2 days ago

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

Eli Lilly announces results from ATTAIN-1, ATTAIN-2 trials of Foundayo

2026-06-07T22:20:58.000Z - 2 days ago

Eli Lilly announces results from ATTAIN-1, ATTAIN-2 trials of Foundayo

Eli Lilly announces ‘positive’ results from Phase 3 trials of retatrutide

2026-06-07T22:15:34.000Z - 2 days ago

Eli Lilly announces ‘positive’ results from Phase 3 trials of retatrutide

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Jun 7, 2026, 11:00 AM EDT - 3 days ago

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story

2026-06-07T11:25:14.000Z - 3 days ago

Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story

NVO

Eli Lilly and Company Transcript: American Diabetes Association (ADA) 86th Scientific Sessions

Jun 6, 2026, 7:00 PM EDT - 3 days ago

Eli Lilly and Company Transcript: American Diabetes Association (ADA) 86th Scientific Sessions

Eli Lilly and Company Slides: American Diabetes Association (ADA) 86th Scientific Sessions

Jun 6, 2026, 7:00 PM EDT - 3 days ago

Eli Lilly and Company Slides: American Diabetes Association (ADA) 86th Scientific Sessions

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Jun 6, 2026, 2:53 PM EDT - 4 days ago

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Jun 6, 2026, 2:34 PM EDT - 4 days ago

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

Jun 6, 2026, 2:30 PM EDT - 4 days ago

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

Jim Cramer Sees Eli Lilly (LLY) Delivering ‘Knockout Punch’ to Competitors

2026-06-05T15:48:08.000Z - 5 days ago

Jim Cramer Sees Eli Lilly (LLY) Delivering ‘Knockout Punch’ to Competitors

NVO

No tech, no problem. Dow makes record and traders think these stocks can lead now

Jun 5, 2026, 7:45 AM EDT - 5 days ago

No tech, no problem. Dow makes record and traders think these stocks can lead now

CNC HUM UNH XLV

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 6 days ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

PFE

Lilly to halve planned €2.3 billion investment in Germany, CEO tells newspaper

Jun 3, 2026, 12:33 PM EDT - 7 days ago

Lilly to halve planned €2.3 billion investment in Germany, CEO tells newspaper

‘Expect More Acquisitions,’ Says Eli Lilly’s (LLY) Top Dealmaker

2026-06-03T14:23:29.000Z - 7 days ago

‘Expect More Acquisitions,’ Says Eli Lilly’s (LLY) Top Dealmaker

Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal

Jun 3, 2026, 9:00 AM EDT - 7 days ago

Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal

Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs

Jun 3, 2026, 7:00 AM EDT - 7 days ago

Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs

Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Jun 3, 2026, 7:00 AM EDT - 7 days ago

Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Focus: GLP-1 drugs may have a beneficial effect across many types of cancer

Jun 3, 2026, 6:05 AM EDT - 7 days ago

Focus: GLP-1 drugs may have a beneficial effect across many types of cancer

NVO

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 7 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

ABBV BIIB ROP

Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees

Jun 2, 2026, 5:43 PM EDT - 8 days ago

Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees

CI NVO

Eli Lilly issues data sharing ultimatum to hospitals, Fierce Healthcare reports

2026-06-02T17:15:51.000Z - 8 days ago

Eli Lilly issues data sharing ultimatum to hospitals, Fierce Healthcare reports

Eli Lilly to spotlight hematology portfolio at EHA Annual Meeting

2026-06-02T14:05:46.000Z - 8 days ago

Eli Lilly to spotlight hematology portfolio at EHA Annual Meeting

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

Jun 2, 2026, 9:30 AM EDT - 8 days ago

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

Eli Lilly Signs Licensing Deal for Intestinal Treatment

2026-06-01T18:58:26.000Z - 9 days ago

Eli Lilly Signs Licensing Deal for Intestinal Treatment

Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals

Jun 1, 2026, 7:04 AM EDT - 9 days ago

Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

May 31, 2026, 8:01 AM EDT - 10 days ago

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients

May 29, 2026, 7:03 AM EDT - 12 days ago

Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients

Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

May 28, 2026, 3:08 PM EDT - 13 days ago

Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

CVS

Eli Lilly and Company Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 28, 2026, 1:30 PM EDT - 13 days ago

Eli Lilly and Company Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

May 28, 2026, 1:00 PM EDT - 13 days ago

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

CVS brings back coverage for Lilly's obesity drug Zepbound

May 28, 2026, 6:47 AM EDT - 13 days ago

CVS brings back coverage for Lilly's obesity drug Zepbound

CVS

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

May 28, 2026, 6:45 AM EDT - 13 days ago

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

CVS

Foundayo and Zepbound now covered for millions of Americans

May 28, 2026, 6:45 AM EDT - 13 days ago

Foundayo and Zepbound now covered for millions of Americans

4 Stocks To Buy Before The S&P 500 Hits 8,000

May 27, 2026, 2:00 PM EDT - 14 days ago

4 Stocks To Buy Before The S&P 500 Hits 8,000

BX GEV PLTR

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026, 11:15 AM EDT - 14 days ago

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

Healthy Returns: Eli Lilly makes a new push into vaccines – here's what to know

May 27, 2026, 10:57 AM EDT - 14 days ago

Healthy Returns: Eli Lilly makes a new push into vaccines – here's what to know

Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine

May 27, 2026, 10:08 AM EDT - 14 days ago

Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine

Goldman Sachs reveals its top non-AI stocks

May 26, 2026, 11:08 PM EDT - 14 days ago

Goldman Sachs reveals its top non-AI stocks

CHWY FTNT

Lilly Gets Back Into the Vaccine Business With New Deals

May 26, 2026, 10:44 AM EDT - 15 days ago

Lilly Gets Back Into the Vaccine Business With New Deals

Lilly Agrees to Buy Trio of Vaccine Developers

May 26, 2026, 8:29 AM EDT - 15 days ago

Lilly Agrees to Buy Trio of Vaccine Developers

Intel, Exxon, and 10 More Stocks That Explain Today's Market

May 26, 2026, 8:11 AM EDT - 15 days ago

Intel, Exxon, and 10 More Stocks That Explain Today's Market

COP CVX DELL INTC MSGS MU OXY

Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

May 26, 2026, 7:50 AM EDT - 15 days ago

Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push

May 26, 2026, 6:50 AM EDT - 15 days ago

Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push

Lilly announces three acquisitions to build infectious disease portfolio

May 26, 2026, 6:45 AM EDT - 15 days ago

Lilly announces three acquisitions to build infectious disease portfolio

Lilly Agrees to Buys Trio of Vaccine Developers

May 26, 2026, 6:35 AM EDT - 15 days ago

Lilly Agrees to Buys Trio of Vaccine Developers

MF__DOOM
MF__DOOM Jun. 10 at 9:59 PM
$NVO $LLY careful in both
0 · Reply
ripster47
ripster47 Jun. 10 at 8:09 PM
$LLY Bullish Trade on Morgan Stanley’s Overweight Rating & $LULU Earnings Curl Long Setup! Watch the video to learn how to trade this repeatable pattern 🎯 https://x.com/TENETTRADEGROUP/status/2064801272528814173?s=20
0 · Reply
FibonacciTrader_
FibonacciTrader_ Jun. 10 at 7:32 PM
FiercePharma just dropped an update on the weekly charts for $NVO’s Oral Wegovy and $LLY’s Foundayo. Quick note: the latest week only includes 4 business days because of Memorial Day, so interpret the volume/units data with that in mind. Even with the shortened week, these names are showing strong traction in the obesity treatment space, worth tracking for trends and potential upside in pharma plays.
0 · Reply
SecEdgarWhisperer
SecEdgarWhisperer Jun. 10 at 7:19 PM
$LLY As stated before.. ripe for shorting.. I am waiting for the trend reversal confirmation but this could be the begining of market coming to senses and start the distribution..
0 · Reply
janthony23
janthony23 Jun. 10 at 5:33 PM
$LLY - Adding to already large position https://finviz.com/news/360902/zepbound-tirzepatide-and-shaquille-oneal-launch-national-campaign-after-nba-legend-learns-the-obstructive-sleep-apnea-he-has-lived-with-for-years-is-treatable
0 · Reply
janthony23
janthony23 Jun. 10 at 5:06 PM
$LLY + $NVDA https://247wallst.com/investing/2026/06/10/i-would-rebuild-my-portfolio-with-just-these-3-stocks-if-i-lost-everything-tomorrow/
0 · Reply
Pennysluts
Pennysluts Jun. 10 at 4:25 PM
$LLY
0 · Reply
Nosecandy_Bear
Nosecandy_Bear Jun. 10 at 4:07 PM
$LLY $NVO it’s simple! Buy Lilly and hold forever.
0 · Reply
freedomtrader6
freedomtrader6 Jun. 10 at 3:40 PM
$NVO $LLY $HIMS This GLP-1 demand story is getting crazier by the week 🚨 Wegovy pill already has 10,000+ people on a UK waiting list… and it’s not even approved yet. What stood out to me most: 75% of people waiting have NEVER used a GLP-1 before Approval could happen within weeks according to Chemist4U CEO That tells me this isn’t just existing users switching formats… This market is EXPANDING fast Feels like we’re still early in the obesity drug adoption curve, honestly.
2 · Reply
SwingTraderPro1
SwingTraderPro1 Jun. 10 at 3:16 PM
Almost done with my Eli Lilly deep dive Been a long ride holding $NVO - one of the toughest positions in my portfolio. Thesis still intact, but wanted to stress-test it fully. How? By studying the competitor: $LLY. Spent 2 months digging into their business, pipeline, and strategy. Came out understanding $NVO, $LLY, and the GLP-1 space on a whole new level. This deep dive will be a must-read for $NVO or $LLY holders- and anyone looking to navigate the GLP-1 boom. Dropping later this week. Stay tuned.
0 · Reply
MF__DOOM
MF__DOOM Jun. 10 at 3:05 PM
$NVO out now sold $43 strike calls bought Monday from $.20 to $1.20 just now nice two day hold for 600% gain $SPY $QQQ $LLY $JPM
0 · Reply
P0rNsTaR
P0rNsTaR Jun. 10 at 2:43 PM
$ABVX everyday. Same morning dip. Then ends up green. Lol $LLY
0 · Reply
Charterdi3
Charterdi3 Jun. 10 at 2:43 PM
$GOOGL $AMC $LLY
0 · Reply
Elevator_up
Elevator_up Jun. 10 at 2:29 PM
$VKTX $LLY This conversation features David Ricks, the CEO of Eli Lilly, discussing the company's historic rise, the impact of GLP-1 therapies, and the future of healthcare innovation. • Worthwhile interview - discussion of the current status of the GLP-1 market, pricing, and expansion of indications into the future. Also, the importantance of the July 1 date when Medicare pricing commences. https://youtu.be/llLg-ptTmRE?si=lrW_cJPpqZDrmm12
0 · Reply
MF__DOOM
MF__DOOM Jun. 10 at 1:56 PM
$NVO happy Wednesday ding ding ding $43 calls printed from Monday $SPY $QQQ $LLY $VIX
0 · Reply
MF__DOOM
MF__DOOM Jun. 10 at 1:55 PM
$LLY $NFLX $NVO $SPY $TSLA gapping up as said this Monday on high watch
0 · Reply
focafoca99
focafoca99 Jun. 10 at 1:46 PM
$LLY featured Shaquille O'Neal in a national campaign to raise awareness of moderate-to-severe obstructive sleep apnea with Zepbound. https://www.rapidticker.com/news/lly-zepbound-tirzepatide-and-shaquille-oneal-7449b1
0 · Reply
ZacksResearch
ZacksResearch Jun. 10 at 1:40 PM
"$LLY just made eczema treatment a lot more convenient — and that could be a big win for adoption 🚀 ✅ FDA approved Ebglyss maintenance dosing once every 8 weeks, down from every 4 weeks 📉 As few as 6 maintenance injections per year while maintaining long-term disease control 🔬 Extension-study data showed durable efficacy with no new safety signals or treatment discontinuations due to adverse events 📈 Access now reaches 94% of commercially insured patients through major PBM agreements Latest LLY news here👉 " https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-38365&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38365
0 · Reply
Makingmillions192
Makingmillions192 Jun. 10 at 1:35 PM
$LEXX $LLY $MRK $NVO Pay attention big pharma 👀
0 · Reply
BioRich
BioRich Jun. 10 at 1:25 PM
$GUTS New to Fractyl, I suggest taking a look at their Corporate Presentation. https://ir.fractyl.com/static-files/832aa780-1e7f-49e7-9e62-d2af6f527d44 Truly a remarkable story of targeted market need and reliably consistent pipeline progression on the cusp of market shaking pivotal trial result and likely FDA adoption. Listen to one call with the CEO and you'll know why the confidence is not only high with this gem, but also why I have it ranked as my #1 Bio, and #1 Overall. $XBI $LLY $NVO $GPCR
0 · Reply
Mike22332233
Mike22332233 Jun. 10 at 11:04 AM
$VNDA The Home Run for the $VNDA BO may very well be Tradipiant for GLP-1 nausea …. $PFE & $LLY have a great need for this drug ALONG with BYSANTI … The SUPER-HUGE market for tradipitant will be the $15 BILLION GLP-1 nausea market today, which is projected at GROWING to $45-$60 BILLION by 2030!!! That is why a GL-1 Pharma will do a buyout soon !! ….. It will end up being a blockbuster drug against GLP-1 nausea … top-line results from a Phase II study indicated that Vandas’ tradipitant was effective at reducing vomiting and nausea caused by GLP-1 receptor agonists like Wegovy in adults … FOLLOW me 👉 @Mike22332233 for latest info AND, nobody is thinking of this .... ALMOST ALL Cancer Chemo/Drugs have some amount of nausea associated with them .... AND HOLD STEADY as I tell you the market size here .... In 2025, worldwide spending on oncology medicines (at list prices) reached $252 billion and is projected to potentially reach nearly $700 billion by 2034 ....
0 · Reply
Chewbanka
Chewbanka Jun. 10 at 9:43 AM
$LLY expecting some significant market shifting to land here this week.
0 · Reply